Advertisement

Do We Need Heart Teams for Complex Cardiac Arrhythmias? A Cardiologist’s Perspective

  • Mark Ainslie
  • Jennifer L. Reed
  • Krystina B. Lewis
  • David Hugh BirnieEmail author
Chapter

Abstract

In many academic cardiovascular centers, there has been a long-standing tradition of collaboration in the management of patients with complex arrhythmias. More recently, there have been initiatives at our institution and others to extend this further, i.e., create a formal “heart team” approach. The ultimate goal is to provide high-quality, evidence-based, timely, cost-effective, personalized care to patients with complex arrhythmias. This chapter will review three areas where the heart team has a key role in the management of complex cardiac arrhythmias:
  1. (i)

    Atrial fibrillation

     
  2. (ii)

    Ventricular arrhythmias

     
  3. (iii)

    Inherited arrhythmia syndromes (IAS)

     

The complex arrhythmia heart team approach has already been shown to be cost-effective in a number of areas. The hope is that the concept of the “complex arrhythmia heart team” will continue to evolve and grow at our institution and others. Going forward, we hope to convince healthcare administrators and funders that savings achieved by the team should, at least in part, be directed to support the team. In the meantime, we will continue to focus on our ultimate goal to provide high-quality, evidence-based, timely, cost-effective, personalized care to patients with complex arrhythmias.

Keywords

Complex arrhythmias Atrial fibrillation Ventricular arrhythmias Inherited arrhythmia syndromes Cost-effective Shared decision-making 

References

  1. 1.
    Fumagalli S, Chen J, Dobreanu D, Madrid AH, Tilz R, Dagres N. The role of the arrhythmia team, an integrated, multidisciplinary approach to treatment of patients with cardiac arrhythmias: results of the European Heart Rhythm Association survey. Europace. 2016;18(4):623–7.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.CrossRefGoogle Scholar
  3. 3.
    Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–7.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRefPubMedGoogle Scholar
  5. 5.
    Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275–444.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ, et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. Eur Heart J. 2013;34(35):2725–30.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007;153(6):1006–12.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Vizel’ AA, Nasretdinova GR, Islamova LV, Vizel’ EA. [Evaluation of the efficiency of various treatment regimens for patients with newly-detected sarcoidosis in the Republic of Tatarstan]. Probl Tuberk Bolezn Legk. 2006(4):19–23. [Article in Russian].Google Scholar
  10. 10.
    Al-Mallah MH, Farah I, Al-Madani W, Bdeir B, Al Habib S, Bigelow ML, et al. The impact of nurse-led clinics on the mortality and morbidity of patients with cardiovascular diseases: a systematic review and meta-analysis. J Cardiovasc Nurs. 2016;31(1):89–95.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Watanabe H, Chinushi M, Izumi D, Sato A, Okada S, Okamura K, et al. Decrease in amplitude of intracardiac ventricular electrogram and inappropriate therapy in patients with an implantable cardioverter defibrillator. Int Heart J. 2006;47(3):363–70.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Il’kovich MM, Perlei VE, Amosov VI, Lebedeva EV. [Early diagnosis of pulmonary hemodynamic disorders in patients with pulmonary sarcoidosis]. Probl Tuberk Bolezn Legk. 2006(4):45–50. [Article in Russian].Google Scholar
  13. 13.
    Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet. 2014;384(9943):583–90.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J. 2012;33(21):2692–9.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Hendriks JM, Vrijhoef HJ, Crijns HJ, Brunner-La Rocca HP. The effect of a nurse-led integrated chronic care approach on quality of life in patients with atrial fibrillation. Europace. 2014;16(4):491–9.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Hendriks J, Tomini F, van Asselt T, Crijns H, Vrijhoef H. Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. Europace. 2013;15(8):1128–35.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C, et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet. 2015;385(9970):775–84.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Gronefeld GC, Hohnloser SH. Quality of life in atrial fibrillation: an increasingly important issue. Eur Heart J Suppl. 2003;5:H25–33.CrossRefGoogle Scholar
  19. 19.
    Healey JS, Parkash R, Pollak T, Tsang T, Dorian P, Committee CCSAFG. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: etiology and initial investigations. Can J Cardiol. 2011;27(1):31–7.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Dabrowski R, Smolis-Bak E, Kowalik I, Kazimierska B, Wojcicka M, Szwed H. Quality of life and depression in patients with different patterns of atrial fibrillation. Kardiol Pol. 2010;68(10):1133–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Ariansen I, Dammen T, Abdelnoor M, Tveit A, Gjesdal K. Mental health and sleep in permanent atrial fibrillation patients from the general population. Clin Cardiol. 2011;34(5):327–31.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119(5):448 e1–19.CrossRefGoogle Scholar
  23. 23.
    Kang Y, Bahler R. Health-related quality of life in patients newly diagnosed with atrial fibrillation. Eur J Cardiovasc Nurs. 2004;3(1):71–6.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36(4):1303–9.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Reed JL, Mark AE, Reid RD, Pipe AL. The effects of chronic exercise training in individuals with permanent atrial fibrillation: a systematic review. Can J Cardiol. 2013;29(12):1721–8.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Giacomantonio NB, Bredin SS, Foulds HJ, Warburton DE. A systematic review of the health benefits of exercise rehabilitation in persons living with atrial fibrillation. Can J Cardiol. 2013;29(4):483–91.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Risom SS, Zwisler AD, Johansen PP, Sibilitz KL, Lindschou J, Gluud C, et al. Exercise-based cardiac rehabilitation for adults with atrial fibrillation. Cochrane Database Syst Rev. 2017;2:CD011197.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Lowres N, Neubeck L, Freedman SB, Briffa T, Bauman A, Redfern J. Lifestyle risk reduction interventions in atrial fibrillation: a systematic review. Eur J Prev Cardiol. 2012;19(5):1091–100.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Skielboe AK, Bandholm TQ, Hakmann S, Mourier M, Kallemose T, Dixen U. Cardiovascular exercise and burden of arrhythmia in patients with atrial fibrillation—a randomized controlled trial. PLoS One. 2017;12(2):e0170060.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64(21):2222–31.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol. 2015;66(9):985–96.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159–69.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018;01:01.Google Scholar
  35. 35.
    Risom SS, Zwisler AD, Rasmussen TB, Sibilitz KL, Madsen TLS, Svendsen JH, et al. Cardiac rehabilitation versus usual care for patients treated with catheter ablation for atrial fibrillation: results of the randomized CopenHeart. Am Heart J. 2016;181:120–9.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Wagner MK, Zwisler ADO, Risom SS, Svendsen JH, Christensen AV, Berg SK. Sex differences in health status and rehabilitation outcomes in patients with atrial fibrillation treated with ablation: results from the CopenHeartRFA trial. Eur J Cardiovasc Nurs. 2018;17(2):123–35.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013;36(1):122–33.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Meyer T, Lauschke J, Ruppert V, Richter A, Pankuweit S, Maisch B. Isolated cardiac sarcoidosis associated with the expression of a splice variant coding for a truncated BTNL2 protein. Cardiology. 2008;109(2):117–21.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Allessie M, Ausma J, Schhotten U. Electrical, contractile and structural remodelling during atrial fibrillation. Cardiovasc Res. 2002;54(2):230–46.PubMedCrossRefGoogle Scholar
  41. 41.
    Haegeli L. CardioPulse. Percutaneous radiofrequency catheter ablation of atrial fibrillation. Eur Heart J. 2012;33(21):2625–7.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009;2(4):349–61.PubMedCrossRefGoogle Scholar
  43. 43.
    Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(2):e004549.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Williams JM, Ungerleider RM, Lofland GK, Cox JL. Left atrial isolation: new technique for the treatment of supraventricular arrhythmias. J Thorac Cardiovasc Surg. 1980;80(3):373–80.PubMedGoogle Scholar
  45. 45.
    Cox JL. The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg. 1991;101(4):584–92.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Damiano RJ Jr, Gaynor SL, Bailey M, Prasad S, Cox JL, Boineau JP, et al. The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox Maze procedure. J Thorac Cardiovasc Surg. 2003;126(6):2016–21.PubMedCrossRefGoogle Scholar
  47. 47.
    Ballaux PK, Geuzebroek GS, van Hemel NM, Kelder JC, Dossche KM, Ernst JM, et al. Freedom from atrial arrhythmias after classic Maze III surgery: a 10-year experience. J Thorac Cardiovasc Surg. 2006;132(6):1433–40.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Fragakis N, Pantos I, Younis J, Hadjipavlou M, Katritsis DG. Surgical ablation for atrial fibrillation. Europace. 2012;14(11):1545–52.PubMedCrossRefGoogle Scholar
  49. 49.
    Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB Jr, et al. Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. J Thorac Cardiovasc Surg. 2005;130(3):797–802.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation. 2012;125(1):23–30.PubMedCrossRefGoogle Scholar
  51. 51.
    Cox JL. Intraoperative options for treating atrial fibrillation associated with mitral valve disease. J Thorac Cardiovasc Surg. 2001;122(2):212–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Kong MH, Lopes RD, Piccini JP, Hasselblad V, Bahnson TD, Al-Khatib SM. Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc Ther. 2010;28(5):311–26.PubMedCrossRefGoogle Scholar
  53. 53.
    Kimura K, Tanabe-Hayashi Y, Noma S, Fukuda K. Images in cardiovascular medicine. Rapid formation of left ventricular giant thrombus with Takotsubo cardiomyopathy. Circulation. 2007;115(23):e620–e1.PubMedCrossRefGoogle Scholar
  54. 54.
    Driver K, Mangrum JM. Hybrid approaches in atrial fibrillation ablation: why, where and who? J Thorac Dis. 2015;7(2):159–64.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Khoynezhad A, Ellenbogen KA, Al-Atassi T, Wang PJ, Kasirajan V, Wang X, et al. Hybrid atrial fibrillation ablation: current status and a look ahead. Circ Arrhythm Electrophysiol. 2017;10(10):pii:e005263.CrossRefGoogle Scholar
  56. 56.
    Jiang YQ, Tian Y, Zeng LJ, He SN, Zheng ZT, Shi L, et al. The safety and efficacy of hybrid ablation for the treatment of atrial fibrillation: A meta-analysis. PLoS One. 2018;13(1):e0190170.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Blackshear J, Odell J. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol. 2015;66(21):2271–81.PubMedCrossRefGoogle Scholar
  59. 59.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefGoogle Scholar
  60. 60.
    Maura G, Blotiere PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015;132(13):1252–60.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circulation. 2013;127(6):720–9.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention. 2016;11(10):1170–9.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Lehmann LH, Riess H, Sturm I. Sickle cell disease, pulmonary hypertension, and sarcoidosis. Ann Hematol. 2008;87(7):591–2.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31(2):372–9.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med. 2007;13(5):434–8.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Kusa S, Miller MA, Whang W, Enomoto Y, Panizo JG, Iwasawa J, et al. Outcomes of ventricular tachycardia ablation using percutaneous left ventricular assist devices. Circ Arrhythm Electrophysiol. 2017;10(6):pii:e004717.CrossRefGoogle Scholar
  68. 68.
    Maury P, Leobon B, Duparc A, Delay M, Galinier M. Epicardial catheter ablation of ventricular tachycardia using surgical subxyphoid approach. Europace. 2007;9(4):212–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Baughman RP, Lower EE. Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med. 2007;13(5):439–44.PubMedCrossRefGoogle Scholar
  70. 70.
    Thiene G, Corrado D, Basso C. Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Orphanet J Rare Dis. 2007;2:45.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Anter E, Hutchinson MD, Deo R, Haqqani HM, Callans DJ, Gerstenfeld EP, et al. Surgical ablation of refractory ventricular tachycardia in patients with nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4(4):494–500.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Liang JJ, Betensky BP, Muser D, Zado ES, Anter E, Desai ND, et al. Long-term outcome of surgical cryoablation for refractory ventricular tachycardia in patients with non-ischemic cardiomyopathy. Europace. 2018;20(3):e30–41.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Ziv O, Dizon J, Thosani A, Naka Y, Magnano AR, Garan H. Effects of left ventricular assist device therapy on ventricular arrhythmias. J Am Coll Cardiol. 2005;45(9):1428–34.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Shirazi JT, Lopshire JC, Gradus-Pizlo I, Hadi MA, Wozniak TC, Malik AS. Ventricular arrhythmias in patients with implanted ventricular assist devices: a contemporary review. Europace. 2013;15(1):11–7.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Bedi M, Kormos R, Winowich S, McNamara DM, Mathier MA, Murali S. Ventricular arrhythmias during left ventricular assist device support. Am J Cardiol. 2007;99(8):1151–3.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Sacher F, Reichlin T, Zado ES, Field ME, Viles-Gonzalez JF, Peichl P, et al. Characteristics of ventricular tachycardia ablation in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol. 2015;8(3):592–7.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Raissi Shabari F, Yousef J, Cohn W, Gregoric I, Frazier OH, Cheng J, et al. Open chest epicardial ablation of ventricular tachycardia early after left ventricular assist device implantation. J Heart Lung Transplant. 2013;32(4):S272.CrossRefGoogle Scholar
  78. 78.
    Herweg B, Ilercil A, Kristof-Kuteyeva O, Rinde-Hoffman D, Caldeira C, Mangar D, et al. Clinical observations and outcome of ventricular tachycardia ablation in patients with left ventricular assist devices. Pacing Clin Electrophysiol. 2012;35(11):1377–83.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):e85–108.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Nunn LM, Lambiase PD. Genetics and cardiovascular disease—causes and prevention of unexpected sudden adult death: the role of the SADS clinic. Heart. 2011;97(14):1122–7.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Behr ER, Dalageorgou C, Christiansen M, Syrris P, Hughes S, Tome Esteban MT, et al. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. Eur Heart J. 2008;29(13):1670–80.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Hendriks KS, Hendriks MM, Birnie E, Grosfeld FJ, Wilde AA, van den Bout J, et al. Familial disease with a risk of sudden death: a longitudinal study of the psychological consequences of predictive testing for long QT syndrome. Heart Rhythm. 2008;5(5):719–24.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. Am J Med Genet A. 2009;149A(4):602–12.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Adler A, Sadek MM, Chan AY, Dell E, Rutberg J, Davis D, et al. Patient outcomes from a specialized inherited arrhythmia clinic. Circ Arrhythm Electrophysiol. 2016;9(1):e003440.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–1.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44(5):681–92.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. Patient Educ Couns. 2006;60(3):301–12.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Masoudi FA, Calkins H, Kavinsky CJ, Drozda JP Jr, Gainsley P, Slotwiner DJ, et al. 2015 ACC/HRS/SCAI left atrial appendage occlusion device societal overview. Heart Rhythm. 2015;12(10):e122–36.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):1677–749.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Bennett M, Parkash R, Nery P, Senechal M, Mondesert B, Birnie D, et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 implantable cardioverter-defibrillator guidelines. Can J Cardiol. 2017;33:174–88.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Lampert R, Hayes DL, Annas GJ, Farley MA, Goldstein NE, Hamilton RM, et al. HRS expert consensus statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm. 2010;7(7):1008–26.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Legare F, Stacey D, Turcotte S, Cossi MJ, Kryworuchko J, Graham ID, et al. Interventions for improving the adoption of shared decision making by healthcare professionals. Cochrane Database Syst Rev. 2014;9:CD006732.Google Scholar
  95. 95.
    Kinnersley P, Edwards A, Hood K, Ryan R, Prout H, Cadbury N, et al. Interventions before consultations to help patients address their information needs by encouraging question asking: systematic review. BMJ. 2008;337:a485.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Stacey D, Kryworuchko J, Belkora J, Davison BJ, Durand MA, Eden KB, et al. Coaching and guidance with patient decision aids: a review of theoretical and empirical evidence. BMC Med Inform Decis Mak. 2013;13(Suppl 2):S11.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Elwyn G, O’Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006;333(7565):417.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    O’Neill ES, Grande SW, Sherman A, Elwyn G, Coylewright M. Availability of patient decision aids for stroke prevention in atrial fibrillation: a systematic review. Am Heart J. 2017;191:1–11.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Probst MA, Noseworthy PA, Brito JP, Hess EP. Shared decision-making as the future of emergency cardiology. Can J Cardiol. 2018;34(2):117–24.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Jensen T, Chin J, Ashby L, Long K, Schafer J, Hakim R. Decision memo for percutaneous left atrial appendage (LAA) closure therapy (CAG-00445N). 2016.Google Scholar
  101. 101.
    Institute PCOR. $5 million award from PCORI and AHA establishes center to support better-informed AFib treatment decisions. June 18, 2018. Available from: https://www.pcori.org/news-release/5-million-award-pcori-and-aha-establishes-center-support-better-informed-afib-treatment.
  102. 102.
    Carroll SL, Stacey D, McGillion M, Healey JS, Foster G, Hutchings S, et al. Evaluating the feasibility of conducting a trial using a patient decision aid in implantable cardioverter defibrillator candidates: a randomized controlled feasibility trial. Pilot Feasibility Stud. 2017;3:49.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Jenkins A, Jones J, Mellis BK, Nuanes H, Nowels C, Varosy P, et al. Development and pilot of four decision aids for implantable cardioverter-defibrillators in different media formats. 37th annual meeting of the Society for Medical Decision Making; St Louis, Missouri. 2015.Google Scholar
  104. 104.
    Lewis KB, Birnie D, Carroll SL, Clark L, Kelly F, Gibson P, et al. User-centered development of a decision aid for patients facing implantable cardioverter-defibrillator replacement: a mixed-methods study. J Cardiovasc Nurs. 2018;33(5):481–91.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    When to consider implantable cardioverter defibrillator (ICD) deactivation: a guide for patients and family. Toronto, ON: CorHealth; 2018.Google Scholar
  106. 106.
    Implantable cardioverter defibrillator deactivation: a guide for health care professionals. Toronto, ON: Cardiac Care Network; 2017.Google Scholar
  107. 107.
    Legare F, Stacey D, Forest PG, Coutu MF, Archambault P, Boland L, et al. Milestones, barriers and beacons: shared decision making in Canada inches ahead. Z Evid Fortbild Qual Gesundhwes. 2017;123–124:23–7.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Elwyn G, Scholl I, Tietbohl C, Mann M, Edwards AG, Clay C, et al. “Many miles to go …”: a systematic review of the implementation of patient decision support interventions into routine clinical practice. BMC Med Inform Decis Mak. 2013;13(Suppl 2):S14.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Joseph-Williams N, Lloyd A, Edwards A, Stobbart L, Tomson D, Macphail S, et al. Implementing shared decision making in the NHS: lessons from the MAGIC programme. BMJ. 2017;357:j1744.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Friedman DJ, Al-Khatib SM. Measuring quality in electrophysiology. J Interv Card Electrophysiol. 2016;47:5–10.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Society CC. Quality project. Available from: http://www.ccs.ca/en/health-policy/programs-and-initiatives/quality-project. Accessed 20 July 2017.
  112. 112.
    Mehaffey JH, Hawkins RB, Byler M, Smith J, Kern JA, Kron I, et al. Amiodarone protocol provides cost-effective reduction in postoperative atrial fibrillation. Ann Thorac Surg. 2018;105(6):1697–702.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Mark Ainslie
    • 1
  • Jennifer L. Reed
    • 2
  • Krystina B. Lewis
    • 3
  • David Hugh Birnie
    • 4
    Email author
  1. 1.Lancashire Cardiac Centre, Department of Cardiac ElectrophysiologyBlackpoolUK
  2. 2.University of Ottawa Heart Institute, Department of Exercise Physiology and Cardiovascular Health Lab, Division of Cardiac Prevention and RehabilitationOttawaCanada
  3. 3.University of Ottawa School of NursingOttawaCanada
  4. 4.Division of CardiologyUniversity of Ottawa Heart InstituteOttawaCanada

Personalised recommendations